Cemiplimab-Rwlc FDA approval date

The FDA approved Cemiplimab-Rwlc (Libtayo) on 28 Sep 2018.

FDA approval date
28 Sep 2018

Drug identity checked against registry records

Also recorded as Libtayo; REGN2810

Included trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2018-09-28DayCemiplimab-RwlcFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "BLA761097", "applicant_as_listed_by_fda": "REGENERON PHARMACEUTICALS", "brand_names": ["LIBTAYO"], "active_ingredients": ["CEMIPLIMAB-RWLC"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20180928", "matched_on": "drug name equals FDA sole active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026